Magazine article from our research archive:

Novavax Reports Positive Results for its VLP-based Trivalent Flu Vaccine Candidate

VACCINE REPORT

Novavax, Inc. (Rockville, MD) has received positive results from an immunogenicity study in ferrets inoculated with the company's trivalent seasonal influenza vaccine candidate made using its proprietary virus-like particle (VLP) technology. These findings will enable Novavax to complete its planned investigational new drug (IND) application to support initiation of a Phase 2 clinical trial targeted to begin in the third quarter of this year.

VLPs may have many advantages over traditional vaccines. Because VLPs more ...

Related newspaper, magazine, and journal articles:

See all results. Or, try our Advanced Search.

Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 60 million articles! Access over 3,500 publications with a FREE trial!